UBS Group
NMRA icon

UBS Group’s Neumora Therapeutics NMRA Stock Holding History

UBS Group’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,000
Closed -$127K – 10561
2024
Q4 		$127K Buy
+12,000
New +$144K ﹤0.01% 6725

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return

UBS Group's NMRA Position: Q1 2026 in Review

UBS Group reduced its Neumora Therapeutics (NMRA) stake by 37% in Q1 2026, selling an estimated $91.5K and leaving 59,584 shares worth $116K. The position accounts for ﹤0.01% of the portfolio, ranked #6931.

UBS Group first reported a position in NMRA in Q4 2023 and has held it in 10 quarters since. The position peaked at $13.2M in Q4 2024. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

  • UBS Group held 59,584 shares of Neumora Therapeutics worth $116K as of Q1 2026.
  • UBS Group sold 35,322 Neumora Therapeutics shares in Q1 2026, an estimated $91.5K.
  • Neumora Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6931 holding.
  • UBS Group first reported a position in Neumora Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • UBS Group's Neumora Therapeutics position peaked at $13.2M in Q4 2024.
  • 114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.